Urothelial Carcinoma (2026): Types, Symptoms, Diagnosis & Treatment

Medically reviewed content · Published 2026 · Last reviewed August 2026

Urothelial carcinoma is a cancer that begins in the urothelial cells lining much of the urinary tract most commonly the bladder, but also the renal pelvis (the part of the kidney that collects urine) and the ureters (the tubes carrying urine from the kidneys to the bladder), and less commonly parts of the urethra. Urothelial carcinoma is the current preferred medical term; transitional cell carcinoma (TCC) is an older term for the same cancer that many patients will still encounter on pathology reports or in older sources, they refer to the same disease, not two different ones. How urothelial carcinoma behaves, and how it’s treated, depends heavily on exactly where it starts and how far it has grown or spread — a small, superficial bladder tumor and an invasive upper urinary tract tumor are managed very differently, even though both are the same underlying cancer type.

This guide explains the different types and locations of urothelial carcinoma, how it’s diagnosed, graded, and staged, and current treatment options including TURBT, BCG, radical cystectomy, bladder-preserving therapy, and the systemic therapies (including newer antibody-drug conjugates and immunotherapy combinations) that have meaningfully changed advanced-disease treatment in recent years along with what treatment and its cost look like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation.

Where Does Urothelial Carcinoma Develop?

• Bladder — the most common site by far
• Renal pelvis — the funnel-shaped part of the kidney where urine collects before entering the ureter
• Ureter — the tubes connecting each kidney to the bladder
• Urethra — urothelial carcinoma can occur in selected portions of the urethra but is much less common than bladder disease

Urothelial carcinoma arising in the renal pelvis or ureter is grouped together as upper tract urothelial carcinoma (UTUC) — a genuinely important distinction from bladder disease, discussed throughout this guide, since UTUC uses different diagnostic tools and, often, different surgery than bladder-based disease. Not every cancer found in the urinary tract is urothelial carcinoma — squamous cell carcinoma and adenocarcinoma can also occur in the bladder, though they’re considerably less common and are managed differently.

Types of Urothelial Carcinoma: Location and Disease Extent

Beyond anatomic location (bladder, upper tract, or urethral), bladder urothelial carcinoma is further classified clinically by how deeply it has grown into the bladder wall — this is a classification of disease extent and behavior, not a separate set of cancers:

• Non-muscle-invasive bladder cancer (NMIBC)
• Muscle-invasive bladder cancer (MIBC)
• Locally advanced disease
• Metastatic disease

Non-muscle-invasive vs. muscle-invasive disease

NMIBC refers to bladder cancer that has not invaded the muscularis propria — the muscle layer of the bladder wall. It includes three categories:

• Ta — non-invasive papillary urothelial carcinoma, growing as a projection into the bladder cavity without invading the wall
• Tis (carcinoma in situ, CIS) — a flat, high-grade lesion. It’s worth being direct here: CIS is not “pre-cancer” — it is a form of high-grade cancer that simply hasn’t formed an obvious raised mass, which is exactly why it can be harder to detect visually and may need cytology or targeted biopsy to identify.
• T1 — tumor invades the lamina propria (the layer just beneath the surface) but not yet the deeper muscularis propria

MIBC generally refers to urothelial carcinoma that has invaded the muscularis propria — typically T2 stage or higher. This distinction changes treatment substantially: NMIBC is generally managed with bladder-preserving approaches (TURBT with or without intravesical therapy), while MIBC typically requires more extensive treatment, potentially including radical cystectomy, perioperative systemic therapy, or carefully selected bladder-preserving combination therapy.

Papillary tumors project into the bladder’s open space and are often easier to see and sample during cystoscopy. Carcinoma in situ, by contrast, is flat and can be subtle or missed on visual inspection alone, this is part of why urine cytology (discussed below) plays a particularly useful role specifically for CIS and other high-grade disease.

Low-grade vs. high-grade

Separately from stage, urothelial carcinoma is classified by grade — a distinct concept describing how abnormal the cancer cells look under the microscope and how biologically aggressive they’re likely to be, independent of how far the tumor has physically grown. Grade and stage are not interchangeable: a tumor can be low-stage but high-grade (a good example being CIS, which is flat/non-invasive but always high-grade), and grade influences recurrence and progression risk in ways stage alone doesn’t capture.

Symptoms of Urothelial Carcinoma

The most common symptom is blood in the urine (hematuria), which may be visible as pink, red, or dark urine or detected only through testing. Even a single episode of painless blood in the urine should be medically evaluated, although infections, kidney stones, and other non-cancerous conditions can also cause it.

Other symptoms may include:

• Frequent urination or urinary urgency
• Burning or pain while urinating
• Pelvic discomfort
• Flank pain, particularly with upper urinary tract disease
• Urinary obstruction or hydronephrosis
• Unexplained weight loss or fatigue in advanced disease
• Bone, abdominal, or pelvic pain in metastatic disease

Causes and Risk Factors

Smoking is the most significant preventable risk factor for bladder urothelial carcinoma. Tobacco chemicals are filtered through the kidneys and remain in contact with the urinary tract lining.

Other risk factors include:

• Occupational exposure to certain industrial chemicals and aromatic amines
• Previous pelvic radiation
• Certain chemotherapy drugs, particularly cyclophosphamide
• Chronic urinary tract irritation or long-term catheter use
• Lynch syndrome, particularly for upper tract urothelial carcinoma
• Certain chronic infections, including schistosomiasis, which is more strongly linked to squamous cell carcinoma of the bladder

How Urothelial Carcinoma Is Diagnosed

Diagnosis generally involves:

1. Medical history and physical examination
2. Urinalysis and urine cytology
3. Imaging such as CT urography
4. Cystoscopy
5. Transurethral resection of bladder tumor (TURBT), when required
6. Histopathological examination
7. Staging and, when appropriate, molecular or biomarker testing

Cystoscopy and TURBT are particularly important for bladder tumors. TURBT removes visible tumors and provides tissue to determine the cancer’s grade and depth of invasion. Pathology may also identify carcinoma in situ, lymphovascular invasion, or aggressive variant histologies such as micropapillary or plasmacytoid patterns.

How Urothelial Carcinoma Is Staged

Bladder cancer uses the TNM staging system:

• Ta: Non-invasive papillary tumor
• Tis: Carcinoma in situ
• T1: Invasion into the lamina propria
• T2: Invasion into the bladder muscle
• T3: Extension into surrounding fat
• T4: Invasion into nearby organs or structures

Non-muscle-invasive bladder cancer (NMIBC) is also classified as low-, intermediate-, high-, or very-high-risk, based on factors such as tumor grade, size, number, recurrence, CIS, and other pathological features.

Treatment Overview

Treatment depends on the tumor’s location, stage, grade, recurrence risk, kidney function, and overall health.

NMIBC

Treatment may include:

• TURBT
• Intravesical chemotherapy
• BCG immunotherapy
• Regular cystoscopic surveillance
• Radical cystectomy for selected very-high-risk or BCG-unresponsive cases

Muscle-Invasive Bladder Cancer

Treatment commonly involves radical cystectomy with lymph-node removal, combined with appropriate perioperative systemic therapy. Selected patients may instead undergo bladder-preserving trimodality therapy, involving maximal TURBT, radiation, and chemotherapy.

After bladder removal, urinary reconstruction may involve an ileal conduit, continent diversion, or neobladder, depending on individual suitability.

Advanced or Metastatic Disease

Modern systemic treatment may include enfortumab vedotin plus pembrolizumab, platinum-based chemotherapy, immunotherapy, or targeted treatment such as FGFR-directed therapy for eligible patients.

Upper Tract Urothelial Carcinoma

UTUC affects the renal pelvis or ureter and requires a different treatment approach from bladder cancer. Higher-risk disease is commonly treated with radical nephroureterectomy, while carefully selected low-risk patients may undergo kidney-sparing treatment such as endoscopic management or segmental ureterectomy.

Prognosis, Follow-Up and Prevention

Prognosis depends on stage, grade, tumor location, lymph-node involvement, variant histology, and treatment response. Regular surveillance is particularly important for NMIBC because recurrence is common.

Stopping smoking, reducing relevant occupational exposures, and promptly investigating unexplained blood in the urine are important risk-reduction measures.

Urothelial Carcinoma Treatment Cost in India

There is no single “urothelial carcinoma treatment cost” — costs diverge dramatically depending on whether a patient has low-risk NMIBC, muscle-invasive disease requiring cystectomy, or metastatic disease requiring modern systemic therapy. Below is a component breakdown based on currently published figures, which — as with every cost topic in this series — vary considerably between sources and should be treated as directional only.

Why International Patients Consider India for Urothelial Carcinoma Care, and How to Choose a Center

India has developed substantial urologic oncology capability, including TURBT, radical cystectomy (open, laparoscopic, and robotic approaches at leading centers), urinary reconstruction, BCG therapy, and access to modern systemic therapies including immunotherapy — for international patients, the appeal is typically this combination of capability with costs generally lower than the US, UK, or much of Europe. India isn’t automatically “the best” choice for every patient, however; several countries offer strong urologic oncology programs, and the right choice depends on an individual patient’s specific disease stage, budget, and travel considerations.

When evaluating a center for urothelial carcinoma care — in India or anywhere — look for:

• A urologic oncologist and medical oncologist with genitourinary-specific experience, not general urology or general oncology alone
• A uropathologist and genitourinary radiologist
• Cystoscopy/TURBT and, for MIBC, radical cystectomy experience with your preferred surgical approach (open, laparoscopic, or robotic) and urinary diversion options
• Access to current intravesical therapy (BCG) and modern systemic therapies, including immunotherapy and, where relevant, antibody-drug conjugates
• Molecular testing capability for FGFR alterations where relevant to advanced disease
• A genuine multidisciplinary urologic oncology tumor board
• Clinical trial access, where relevant
• Established international patient services (visa letters, coordination, interpreter support)

Verify accreditation, named specialist credentials, and specific radical cystectomy and systemic therapy experience directly with the hospital, rather than relying solely on third-party “top hospital” listicles.

The International Patient Treatment Journey

1. Share existing medical records and pathology for review
2. Confirm urothelial carcinoma diagnosis and identify bladder vs. upper-tract origin
3. Establish grade and stage, including NMIBC vs. MIBC status where applicable
4. Review relevant biomarkers or molecular testing
5. Multidisciplinary specialist review
6. Treatment plan developed, with alternatives explained
7. Hospital and specialist confirmation
8. Written, itemized cost estimate
9. Medical visa guidance
10. Travel and accommodation arrangements
11. Begin treatment
12. Monitor treatment response
13. Continue surveillance
14. Remote follow-up and report-sharing with the home-country physician after returning home

No credible provider can guarantee cure, bladder preservation, an exact treatment duration or final cost, treatment response, visa approval, or survival outcome before reviewing a patient’s actual pathology and imaging — be cautious of any provider offering these guarantees upfront.

Questions to Ask Your Urologic Oncology Team

• Is my cancer confirmed as urothelial carcinoma, and where did it start — bladder or upper urinary tract?
• What is the grade? Is it NMIBC or MIBC, and if NMIBC, what risk category?
• Is carcinoma in situ present?
• What is my full TNM stage? Are lymph nodes involved?
• Do I need a repeat TURBT to confirm muscle status?
• Am I a candidate for BCG, and if my prior BCG didn’t work, what are my options?
• Should radical cystectomy be considered, or could bladder-preserving trimodality therapy be appropriate for me?
• Am I cisplatin-eligible, and how does that affect my treatment options?
• Is molecular/FGFR testing relevant to my situation?
• If advanced or metastatic, would enfortumab vedotin plus pembrolizumab be appropriate, or is chemotherapy the better starting point for me specifically?
• What is my realistic recurrence risk, and what will surveillance involve?

How Shifam Health Helps International Urothelial Carcinoma Patients

Shifam Health is a medical tourism facilitator, not a hospital, urology clinic, cancer treatment center, or pathology laboratory — we don’t diagnose urothelial carcinoma or determine treatment plans.

What we do is help international patients navigate the practical side of accessing urothelial carcinoma care in India: coordinating the review of pathology and imaging by relevant specialists, helping identify hospitals with genuine urologic oncology experience relevant to your specific stage and location of disease, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you or someone you’re caring for has received a urothelial carcinoma diagnosis, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Frequently Asked Questions

People Ask Further Questions

Conclusion

Urothelial carcinoma is a single cancer type that behaves very differently depending on where it starts and how far it has grown — the distinction between bladder and upper tract disease, and between non-muscle-invasive and muscle-invasive disease, shapes nearly every treatment decision that follows. The systemic treatment landscape for advanced disease specifically has changed substantially in just the past two to three years, which makes confirming current, guideline-supported options with your treating oncologist more important than ever.

If you or someone you’re caring for has received a urothelial carcinoma diagnosis, understanding exactly where your disease falls on these distinctions — location, grade, stage, and risk category — is the most useful step before deciding on a treatment path, in India or anywhere else.

This article is for general medical education and does not replace individualized advice from a qualified urologic oncologist or medical oncologist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.